Q-omics provides the consensus-scored CCL23 profile across patient tissues and cancer cell-line models. CCL23 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, CCL23 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, CCL23 RNA expression shows 17,187 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, KICH, and LSCC as cancer lineages where CCL23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCL23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCL23 survival associations across molecular data types. CCL23 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCL23 RNA expression–survival associations across cancer types. High CCL23 expression shows unfavorable associations in LAML, MESO and UVM, but favorable associations in PAAD, SKCM and ACC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify PAAD as the clearest survival context for CCL23 RNA expression.
This table summarizes CCL23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCL23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCL23 shows lower tumor expression in KICH, COAD, KIRC, BLCA, LUAD and KIRP. The KICH box plot shows higher CCL23 RNA expression in normal versus tumor tissue (log2 FC = −2.743, t-test p < 0.001).
This table shows molecular features associated with CCL23 in patient tissues and cancer cell lines. In patient samples, CCL23 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCL23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
